Flag of the European Union EU Clinical Trials Register Help

Clinical trials for VO2 max

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: VO2 max. Displaying page 1 of 1.
    EudraCT Number: 2021-006953-77 Sponsor Protocol Number: 27-12-2021 Start Date*: 2022-04-11
    Sponsor Name:Aarhus University Hospital
    Full Title: Treatment effects of Bisoprolol and Verapamil in symptomatic patients with non-obstructive hypertrophic cardiomyopathy
    Medical condition: Non-obstructive Hypertrophic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007636 Cardiomyopathy PT
    20.0 10007541 - Cardiac disorders 10049813 Non-obstructive cardiomyopathy PT
    27.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    20.0 10007541 - Cardiac disorders 10061029 Cardiomyopathy primary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003406-40 Sponsor Protocol Number: RK2017 Start Date*: 2017-09-08
    Sponsor Name:Université catholique de Louvain
    Full Title: Repetitive blood donations and endurance sport performance: does iron supplementation limit the negative effects on hematological parameters?
    Medical condition: healthy subjects moderately active undergoing repeated blood donations
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002140-40 Sponsor Protocol Number: WADA2013ter Start Date*: 2016-09-17
    Sponsor Name:Bispebjerg University Hospital
    Full Title: Pharmacological properties of in haled and oral terbutalin administrated in healthy trained males
    Medical condition: Pharmacological properties of terbutalin regarding uptake and excretion
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-017924-18 Sponsor Protocol Number: P10 Start Date*: 2011-01-04
    Sponsor Name:
    Full Title: Efficacy assessment of repeat intramyocardial injection of autologous bone marrow cells in previously responding no-option patients with residual refractory angina pectoris and documented ischemia
    Medical condition: In coronary artery disease atherosclerosis leads to a decrease in lumen diameter of the large epicardial arteries, causing a deficit in blood flow known as ischemia. This ischemia can cause chest p...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002091-41 Sponsor Protocol Number: 03618 Start Date*: 2014-10-09
    Sponsor Name:Academisch medisch centrum
    Full Title: Right vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system
    Medical condition: To study the effect of losartan in adult patients with Tetralogy of Fallot and right ventricular dysfunction, defined as right ventricular ejection fraction <50%. Without severe valvular lesions.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005197-63 Sponsor Protocol Number: U1111-1128-8762 Start Date*: 2013-02-25
    Sponsor Name:Ana M. Wägner
    Full Title: Effect of liraglutide on physical performance: a randomised, double-blind, controlled study in patiens with type 2 diabetes.
    Medical condition: Patients with Diabetes type 2.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-015120-28 Sponsor Protocol Number: 2009-02 Start Date*: 2010-01-25
    Sponsor Name:CENTRE ANTOINE LACASSAGNE
    Full Title: Etude d’un traitement préopératoire par Cisplatine-Docétaxel et radiothérapie dans le cancer bronchique non à petites cellules de stade IIIA/IIIB (T1-4, N2): Etude de phase II
    Medical condition: Cancer bronchique non à petites cellules de stade IIIA/IIIB (T1-T4, N2) jugé potentiellement résécable
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017168-17 Sponsor Protocol Number: GS-US-270-0101 Start Date*: 2010-05-31
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients with Heart Failure with Preserved Ejection Fraction
    Medical condition: Heart failure with Preserved Ejection Fraction
    Disease: Version SOC Term Classification Code Term Level
    12.1 10069211 Diastolic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003418-42 Sponsor Protocol Number: WOE_2013_TUE Start Date*: 2015-03-23
    Sponsor Name:Wörwag Pharma GmbH & Co. KG
    Full Title: Effect of Mg-Orotate administration on cardiocirculatory Performance, the muscular concentration of phosphocreatine and the adaptation of muscle cellular level: A double blind, randomized, placebo-...
    Medical condition: Evaluation of cardiocirculatory performance using clinical and relevant muscle laboratory parameters while taking Mg-Orotate and application of workouts
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005713-40 Sponsor Protocol Number: 69HCL20_1135 Start Date*: 2021-08-02
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure patients on heart transplant waiting list: a multicenter, double-blind, randomized clinical trial.
    Medical condition: for advanced Heart Failure patients on heart transplant waiting list
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-004706-33 Sponsor Protocol Number: RH-HJE-LN-01 Start Date*: 2017-03-31
    Sponsor Name:Finn Gustafsson
    Full Title: The Effect of Ivabradine Treatment on Exercise Capacity in Patients with Cardiac Allograft Vasculopathy after Heart Transplantation
    Medical condition: Cardiac allograft vasculopathy and elevated resting heart rate in heart transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002225-10 Sponsor Protocol Number: EMPA-HEART Start Date*: 2016-09-28
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Impact of empagliflozin on left ventricular functions: a single center, phase III, randomized, open-label, active treatment-controlled, parallel study in patients with type 2 diabetes and normal le...
    Medical condition: type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005682-20 Sponsor Protocol Number: MOR-008 Start Date*: 2012-06-19
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome)
    Medical condition: Mucopolysaccharidosis Type IVA
    Disease: Version SOC Term Classification Code Term Level
    16.0 10010331 - Congenital, familial and genetic disorders 10028095 Mucopolysaccharidosis IV PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020352-59 Sponsor Protocol Number: GHF112670 Start Date*: 2010-07-29
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-center, placebo-controlled study to evaluate the safety of GSK716155 and its effects on myocardial metabolism, myocardial function, and exercise capacity in patients with NYHA Class II/III ...
    Medical condition: NYHA Class II/III congestive heart failure.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-006156-37 Sponsor Protocol Number: FA_BBK_8 Start Date*: 2012-07-10
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: A double-blind, randomized, placebo-controlled, clinical trial to test the efficacy of Epoetin alfa on physical performance of Friedreich Ataxia patients.
    Medical condition: FRIEDREICH ATAXIA
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10008025 Cerebellar ataxia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000137-31 Sponsor Protocol Number: 2017-2019 Start Date*: 2017-12-19
    Sponsor Name:VU University Medical Center
    Full Title: Pulmonary Hypertension REversal in Clusters of Patients With Identical Pathobiological Substrates. 6-Mercaptopurine Proof-of-Concept Trial
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037454 Pulmonary vascular disorders HLGT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006787-25 Sponsor Protocol Number: 16122021 Start Date*: 2022-07-06
    Sponsor Name:Rigshospitalet The Heart Center
    Full Title: Effects of DAPAgliflozin on cardiopulmonary exercise capacity and hemodynamics in Pulmonary Arterial Hypertension: A double blind randomized trial
    Medical condition: Pulmonary arterial hypertension Chronic thromboembolic pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10065150 Associated with pulmonary arterial hypertension LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10065151 Idiopathic pulmonary arterial hypertension LLT
    24.1 10010331 - Congenital, familial and genetic disorders 10085244 Heritable pulmonary arterial hypertension PT
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10068740 CTEPH LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005287-21 Sponsor Protocol Number: Simon1234 Start Date*: 2023-06-01
    Sponsor Name:Rigshospitalet, Center for Aktiv Sundhed, section 7641
    Full Title: Exercise-induced cardiac adaptions in rheumatoid arthritis patients during interleukin-6 vs. tumor necrosis factor antibody therapy: a randomised controlled study (RABEX).
    Medical condition: Rheumatoid Athritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-003314-37 Sponsor Protocol Number: CCM1862 Start Date*: 2023-04-19
    Sponsor Name:CENTRO CARDIOLOGICO SPA FONDAZIONE MONZINO
    Full Title: Effects of combined diuretic therapy on exercise capacity, alveolus-capillary diffusion, and maintenance of euvolemia in chronic congestive heart failure, diuretic therapy compared between loop diu...
    Medical condition: congestive heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000667-24 Sponsor Protocol Number: ST-920-201 Start Date*: 2019-11-12
    Sponsor Name:Sangamo Therapeutics, Inc.
    Full Title: A Phase I/II, Multicenter, Open-Label, SingleDose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, a rAAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects with Fabry Dise...
    Medical condition: Fabry Disease (X-linked lysosomal storage disease)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 20:43:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA